On Jul. 8, 2020, Constant Therapeutics reported that its peptide drug TXA127 was tested in a series of Phase 2 clinical trials in hospitalized COVID-19 patients who are not in the Intensive Care Unit (ICU).

The trials were conducted at medical centers in the U.S., including the Brigham and Womenﾒs Hospital in Boston, Massachusetts; Policlinico S. Orsola-Malpighi Hospital in Bologna, Italy; and at sites in Israel affiliated with Bar-Ilan University and Technion Israel Institute of Technology. Over 400 patients were expected to be recruited.